Protein kinase inhibitor

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

Retrieved on: 
Monday, April 8, 2024
Transforming growth factor beta, Partnership, Acquisition, Cancer, Protein kinase, Windtree Therapeutics, Lung cancer, Note, Therapy, Protein kinase C, PKC, Skin, Protein kinase inhibitor, Security (finance)

The Company also completed a $1.5 million convertible note bridge financing.

Key Points: 
  • The Company also completed a $1.5 million convertible note bridge financing.
  • The acquired Varian asset platform is a novel, potential high-potency, specific, aPKCi with possible broad use in oncology as well as certain rare malignant diseases.
  • “Completion of the Varian asset acquisition and the bridge financing represents a potentially transformative next step for Windtree.
  • Additional details are available by reading the Company’s Current Report on Form 8-K relating to the Varian asset acquisition and senior convertible note bridge financing, which was filed with the Securities and Exchange Commission on April 8, 2024.

Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Status: Authorised

Retrieved on: 
Monday, December 18, 2023
Mantle cell lymphoma, Anatomy, Select, Urine, ATC, Protein kinase inhibitor, Neutrophil, Anemia, BTK, Pneumonia, MCL, International, INN, Disease, Language, Tablet, EMA, Patient, IIA, Marketing, Medical Subject Headings, Diarrhea, Neutropenia, Cancer, Infection, Bruise, Growth, Mouth, Fatigue, Urinary tract infection, Chemotherapy, Instrumentation, Vaccine, Pharmaceutical industry, Medicinal plants, Medical device, Medical imaging, Online shopping, Bookkeeping, Medicine, Lymphoma, Pirtobrutinib

Mantle cell lymphoma is rare, and Jaypirca was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2021.

Key Points: 
  • Mantle cell lymphoma is rare, and Jaypirca was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2021.
  • Treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
  • Treatment should be continued until the disease gets worse or the patient gets unacceptable side effects.
  • Jaypirca : EPAR - Medicine overview
    Product information
    Jaypirca : EPAR - Product information
    This medicine’s product information is available in all official EU languages.

Kinnate Biopharma Inc. to Participate in the 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Tuesday, July 27, 2021
Protein kinase inhibitor, Wedbush Securities

SAN FRANCISCO and SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually from August 10-11, 2021.

Key Points: 
  • SAN FRANCISCO and SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually from August 10-11, 2021.
  • Members of the Kinnate management team will also host investor meetings during the conference.
  • A live webcast of the Wedbush panel discussion will be available in the Investors and Media section of the Kinnate website at www.kinnate.com .
  • Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Tyrosine kinases, Multiple sclerosis, Life sciences, Bruton's tyrosine kinase, Biology, Glial cells, Tyrosine kinase, Multiple sclerosis research, Microglia, Biogen, Protein kinase inhibitor

For over 30 years, Biogen has led in MS research and today has a leading portfolio of MS products.

Key Points: 
  • For over 30 years, Biogen has led in MS research and today has a leading portfolio of MS products.
  • BTK inhibitors may have the potential to transform the treatment paradigm of autoimmune diseases, in particular MS.
  • Orelabrutinib is a small molecule Brutons tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases.
  • Among myeloid cells expressing BTK, microglia, which reside in the CNS, have been shown to express high level of BTK in multiple sclerosis.

Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021

Retrieved on: 
Wednesday, July 7, 2021
Protein kinase inhibitor

SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will participate in the William Blair Biotech Focus Conference 2021, being held virtually from July 14-15, 2021.

Key Points: 
  • SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will participate in the William Blair Biotech Focus Conference 2021, being held virtually from July 14-15, 2021.
  • Members of the Kinnate management team will also host investor meetings during the conference.
  • A live webcast of the William Blair panel discussion will be available in the Investors and Media section of the Kinnate website at www.kinnate.com .
  • Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.

2021 Anaplastic Lymphoma Kinase Inhibitors Pipeline Market Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Pharmaceutical, Health, Oncology, Medical specialties, Lymphoma, Branches of biology, Protein kinase inhibitor, Anaplastic lymphoma kinase, Clinical medicine, Anaplastic large-cell lymphoma, T-cell lymphoma

The "Anaplastic Lymphoma Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anaplastic Lymphoma Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Anaplastic lymphoma kinase inhibitors pipeline landscape.
  • This segment of the report provides insights about the different Anaplastic lymphoma kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Anaplastic lymphoma kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer

Retrieved on: 
Thursday, July 1, 2021
Research, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Organic compounds, Chemical compounds, Clinical medicine, Cancer treatments, Aromatic amines, Chloroarenes, HER2/neu, Breast cancer, Protein kinase inhibitor, Trastuzumab, Neratinib, Trastuzumab emtansine, HER2-Positive Breast Cancer, Puma Biotechnology, HER2-POSITIVE BREAST CANCER, PUMA BIOTECHNOLOGY

HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death.

Key Points: 
  • HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:
    As a single agent, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
  • Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.

AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, June 30, 2021
Tyrosine kinase receptors, Lung cancer, Branches of biology, ROS1, Non-small-cell lung carcinoma, Anaplastic lymphoma kinase, Clinical medicine, Epidermal growth factor receptor, ATM serine/threonine kinase, Targeted therapy, ALK inhibitor, Protein kinase inhibitor

The AmoyDx PLC Panel has received approval for four driver genes (EGFR, ALK, ROS1, and BRAF) for nine associated targeted therapies in NSCLC.

Key Points: 
  • The AmoyDx PLC Panel has received approval for four driver genes (EGFR, ALK, ROS1, and BRAF) for nine associated targeted therapies in NSCLC.
  • With its high sensitivity and short turnaround time, The AmoyDx PLC Panel is expected to be an important clinical diagnostic in guiding treatment opportunities for NSCLC patients.
  • We are pleased to collaborate with AmoyDx and PREMIA in obtaining approval of the AmoyDx PLC Panel in Japan.
  • Detection of EGFR gene mutations, ALK fusion gene, ROS1 fusion gene, and BRAF gene mutations in nucleic acids extracted from cancer tissue

Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires

Retrieved on: 
Monday, June 7, 2021
Life sciences, Pharmaceutical industry, Health sciences, Natural sciences, Medication, Protein kinase inhibitor, Cancer, Biopharmaceutical, Kinase

She has successfully executed over $100 billion in transactions in the biopharmaceutical, medical technology, and tools/diagnostics sectors.

Key Points: 
  • She has successfully executed over $100 billion in transactions in the biopharmaceutical, medical technology, and tools/diagnostics sectors.
  • Kinnate is at an exciting inflection point in its path to becoming a global, clinical-stage biopharmaceutical company.
  • Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Global Waldenstrom Macroglobulinemia (WM) Market Spotlight Report 2021: Treatments, Epidemiology, Disease Background, Pipeline, Recent Events, Opportunity, Clinical Trials, Marketed Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Pharmaceutical, Health, Clinical trials, Tyrosine kinase inhibitors, Chemical compounds, Health sciences, Drugs, Orphan drugs, Lymphoma, Waldenström's macroglobulinemia, Ibrutinib, Protein kinase inhibitor, Bristol Myers Squibb

This Market Spotlight report covers the Waldenstrom Macroglobulinemia (WM) market, comprising key marketed and pipeline drugs, probability of success, clinical trials, upcoming events, recent events and analyst opinion, a 10-year disease incidence forecast, and presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Waldenstrom Macroglobulinemia (WM) market, comprising key marketed and pipeline drugs, probability of success, clinical trials, upcoming events, recent events and analyst opinion, a 10-year disease incidence forecast, and presenting drug-specific revenue forecasts.
  • Imbruvica and tirabrutinib, two small molecule tyrosine kinase inhibitors, are the only marketed drugs for WM.
  • The majority of industry-sponsored drugs in active clinical development for WM are in Phase II, with only two drugs in Phase III.
  • Bristol Myers Squibb, Johnson & Johnson, and Takeda lead the industry sponsors with the highest overall number of clinical trials for WM.